Carcinoembryonic antigen (CEA) is of proven benefit in prognosis and follow up, but has limited sensitivity (30–40%) for detecting early CRC [3,4], whereas serial faecal occult blood testing is proven to reduce CRC mortality but suffers from significant false negative and false positive rates [5]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.